Cargando…
Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
Autores principales: | Hanzel, Jurij, Ma, Christopher, Marshall, John K., Feagan, Brian G., Jairath, Vipul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the AGA Institute
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198394/ https://www.ncbi.nlm.nih.gov/pubmed/32380089 http://dx.doi.org/10.1016/j.cgh.2020.04.033 |
Ejemplares similares
-
A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
por: Hanzel, Jurij, et al.
Publicado: (2023) -
A comparison of approaches for adjudicating outcomes in clinical trials
por: Kahan, Brennan C., et al.
Publicado: (2017) -
Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
por: Ma, Christopher, et al.
Publicado: (2017) -
Gastric ectopic pancreas mimicking a gastrointestinal stromal tumour: A case report
por: Štor, Zdravko, et al.
Publicado: (2018) -
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
por: Bernard, Edmond-Jean, et al.
Publicado: (2020)